Growth Stage

Developing diagnostics and therapeutics for osteoarthritis

Developing diagnostics and therapeutics for osteoarthritis


Raised this Round: Raised: $4,667,638

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Preferred


Series C

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Jupiter, Florida

Business Type


Cytonics Corporation, with a pre-money valuation of $46.7 million, is raising funds on SeedInvest through Reg A+ crowdfunding. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system concentrating A2M from patients’ blood to treat their own damaged joints. Cytonics Corporation was founded by Gaetano Scuderi and has raised over $15 million in previous rounds of financing. The current round of funding has a minimum raise of $1,500,000 and a maximum raise of $19,000,000, and the funds will be used for GMP production of CYT-108, GLP pre-clinical animal study, Phase 1 human clinical trial, and Phase 2 human clinical trial. Cytonics Corporation has already initiated a pilot pre-clinical study for its lead drug candidate CYT-108 in 2019. It is a biologic therapy modeled after the naturally occurring A2M molecule found in the blood.

Balance Sheet

Cash and Cash Equivalents


Investment Securities


Total Investments


Accounts and Notes Receivable




Property, Plant and Equipment (PP&E)


Property and Equipment


Total Assets


Accounts Payable & Accrued Liabilities


Policy Liabilities and Accruals




Long Term Debt


Total Liabilities


Total Stockholders' Equity


Total Liabilities and Equity


Statement of Comprehensive Income Information

Total Revenues


Total Interest Income


Costs & Expenses Applicable to Rev


Total Interest Expenses


Depreciation and Amortization


Net Income


Earnings Per Share - Basic


Earnings Per Share - Diluted


Auditor: D. Brooks and Associates CPA's, P.A.
Financials as of: 07/09/2020
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Cytonics 05/27/2024 StartEngine $65,792,080 $3,626,034 Equity - Preferred Funded RegCF
Cytonics 03/30/2023 Dealmaker Securities $58,915,995 $1,695,868 Equity - Preferred Funded RegCF
Cytonics 10/13/2022 SeedInvest $58,915,996 $2,633,766 Equity - Preferred Funded RegCF / RegD 506(c)
Cytonics 04/29/2021 SeedInvest $46,701,000 $4,667,638 Equity - Preferred Funded RegA+
Cytonics 05/17/2019 SeedInvest $32,400,000 $494,344 Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Cytonics Corporation on SeedInvest
Platform: SeedInvest
Security Type: Equity - Preferred
Valuation: $46,701,000
Price per Share: $2.00

Follow company

Follow Cytonics Corporation on SeedInvest

Buy Cytonics's Deal Report

Warning: according to the close date for this deal, Cytonics may no longer be accepting investments.

Cytonics Deal Report

Get KingsCrowd’s comprehensive report on Cytonics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Cytonics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Cytonics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge